Delcath Systems

Expanded Clinical Trials And Program Integration Will Define Oncology's Future

AnalystConsensusTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

02 May 25

Updated

28 Aug 25

AnalystConsensusTarget's Fair Value

US$24.33

54.7% undervalued

28 Aug

US$11.02

0.2%

-0.9%

0.2%

-0.9%

Author's Valuation

US$24.3

54.7% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

US$24.3

54.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

23.23%

Medical Equipment revenue growth rate

0.44%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.47%

Calculation

US$59.91m

Earnings '28

23.09x

PE Ratio '28

US$1.38b

Market Cap '28

US$1.38b

Market Cap '28

45.81m

No. shares '28

US$30.20

Share Price '28

US$30.20 Share Price '28

Discounted to 2025 @ 7.47% p.a.

US$24.33

Fair Value '25